miR-330 Nucleic Acid Compounds Targeting MYC MRE for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods to target MYC-associated cancers, as there are no drugs available that effectively target the oncogenic effects of the c-MYC protein, which is frequently overexpressed in various tumors, including breast, colon, and liver cancers.
Innovation Solution
Development of novel nucleic acid-based compounds, such as miR-330 mimics, that are highly complementary to MYC microRNA Responsive Elements (MRE) to downregulate MYC expression by administering them via recombinant Adeno-Associated virus (AAV) or as siRNA, targeting specific sequences to inhibit MYC mRNA translation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are used to treat cancer, then general cancer treatment is provided, but effective targeting of MYC-associated cancers is not achieved
Solution Approach 1:
The patent applies local quality by designing nucleic acid compounds with specific sequences that are complementary to MYC MRE sequences. This allows the treatment to have general anti-cancer effects while simultaneously providing specific targeting of MYC-associated cancers through the unique sequence complementarity to MYC regulatory elements.
2Reliability
If nucleic acid compounds with high complementarity to MYC MRE are administered, then MYC expression is effectively downregulated, but delivery and stability challenges arise
Solution Approach 1:
The patent employs composite materials by formulating nucleic acid compounds with protective coatings or conjugating them to delivery vehicles such as lipids or proteins. This composite structure protects the nucleic acid from degradation, improves cellular uptake, and enhances stability in biological environments while maintaining the sequence complementarity needed for MYC downregulation.
3Reliability
If miR-330 compounds are used to target MYC MRE, then cancer cell proliferation is inhibited, but potential off-target effects may occur
Solution Approach 1:
The patent applies preliminary action by conducting in silico screening and in vitro validation to identify and verify the specificity of the nucleic acid compound sequence to MYC MRE sequences before in vivo administration. This preliminary characterization ensures that the compound will selectively target MYC-associated cancers while minimizing potential off-target effects on other cellular processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The miR-330 compounds effectively downregulate MYC expression, inhibiting cancer cell proliferation and inducing cell cycle arrest, providing a potential therapeutic approach for MYC-associated cancers like liver and colorectal cancer.
Implementation Method 1
a nucleic acid sequence having at least 80% complementarity to a microRNA (miR) Responsive Element (MRE) sequence
Implementation Method 2
administering them via recombinant Adeno-Associated virus (AAV)
Data Source
AI summary
Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.